Zacks Investment Research downgraded shares of Halyard Health, Inc. (NYSE:HYH) from a hold rating to a sell rating in a research report released on Tuesday morning.
According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “
Other research analysts also recently issued reports about the stock. TheStreet raised shares of Halyard Health from a c rating to a b rating in a report on Thursday, June 22nd. Stifel Nicolaus reaffirmed a buy rating and issued a $45.00 price objective on shares of Halyard Health in a report on Thursday, September 21st. BidaskClub raised shares of Halyard Health from a hold rating to a buy rating in a report on Saturday, August 19th. Deutsche Bank AG raised their price objective on shares of Halyard Health from $35.00 to $42.00 and gave the stock a buy rating in a report on Thursday, August 3rd. Finally, Stephens raised shares of Halyard Health from an equal weight rating to an overweight rating in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $42.25.
Shares of Halyard Health (NYSE HYH) traded down 1.14% during midday trading on Tuesday, hitting $44.06. The stock had a trading volume of 27,822 shares. Halyard Health has a 52 week low of $31.59 and a 52 week high of $46.63. The stock’s 50-day moving average price is $45.34 and its 200 day moving average price is $40.48. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 42.37 and a beta of 1.75.
Halyard Health (NYSE:HYH) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.14. The company had revenue of $399.20 million during the quarter, compared to the consensus estimate of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. Halyard Health’s revenue for the quarter was down .2% on a year-over-year basis. During the same period last year, the firm earned $0.45 EPS. On average, equities analysts forecast that Halyard Health will post $1.95 earnings per share for the current year.
WARNING: “Halyard Health, Inc. (HYH) Cut to Sell at Zacks Investment Research” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/13/halyard-health-inc-hyh-cut-to-sell-at-zacks-investment-research.html.
A number of large investors have recently made changes to their positions in HYH. Comerica Bank boosted its holdings in Halyard Health by 4.3% in the 1st quarter. Comerica Bank now owns 37,158 shares of the medical instruments supplier’s stock valued at $1,464,000 after purchasing an additional 1,535 shares during the period. Swiss National Bank boosted its holdings in Halyard Health by 1.2% in the 1st quarter. Swiss National Bank now owns 76,900 shares of the medical instruments supplier’s stock valued at $2,929,000 after purchasing an additional 900 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in Halyard Health by 11.3% in the 1st quarter. UBS Asset Management Americas Inc. now owns 34,269 shares of the medical instruments supplier’s stock valued at $1,305,000 after purchasing an additional 3,473 shares during the period. Sei Investments Co. boosted its holdings in Halyard Health by 4.0% in the 1st quarter. Sei Investments Co. now owns 13,209 shares of the medical instruments supplier’s stock valued at $503,000 after purchasing an additional 503 shares during the period. Finally, Mason Street Advisors LLC boosted its holdings in Halyard Health by 1.2% in the 1st quarter. Mason Street Advisors LLC now owns 22,047 shares of the medical instruments supplier’s stock valued at $840,000 after purchasing an additional 263 shares during the period. 91.02% of the stock is owned by hedge funds and other institutional investors.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Get a free copy of the Zacks research report on Halyard Health (HYH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.